Global oligonucleotide synthesis market could reach $2.9billion by 2024

DUBLIN–(BUSINESS WIRE)–The “Oligonucleotide
Synthesis Market by Product (Primer, Probe, Linker, Adaptor, Custom,
Reagent, Equipment), Application (PCR, DNA, RNAi, Research,
Therapeutic), End User (Academic, Pharmaceutical, Biotechnology) –
Global Forecast to 2024” report has been added to ResearchAndMarkets.com’s
offering.

Global oligonucleotide synthesis market is expected to reach $2.9
billion by 2024, at a CAGR of 10.5% during the forecast period of 2019
to 2024.

The growth in oligonucleotide synthesis market is mainly attributed to
the growing adoption of synthesized oligonucleotides in diagnostics and
clinical applications, rising R&D expenditure and government investment
in pharmaceutical and biotechnology companies, plummeting cost of
sequencing, increasing public-private spending on genomics, and rising
venture capital investments/funding.

However, factors such as lack of regulations for commercialization of
therapeutic oligos and price erosion of synthesized oligonucleotides are
likely to hinder the market growth. Moreover, emerging Asian markets are
likely to provide significant growth opportunities. Also, large-scale
synthesis of oligonucleotides, and the delivery of oligonucleotide drugs
to specific targets are the major challenges for this market.

This study provides a detailed analysis of oligonucleotide synthesis
market with respect to various segments on the basis of product,
application, end user, and geography. On the basis of product, the
global oligonucleotide synthesis market is mainly segmented into
synthesized oligonucleotide, reagents, and equipment. The synthesized
oligonucleotide segment is further categorized by product, and by type.
The synthesized oligonucleotide held the largest share of the global
oligonucleotide synthesis market in 2018. The large share of this
segment is mainly attributed to the increased adoption and application
of synthesized oligonucleotides in research, diagnostics, and
therapeutics.

Based on type of application, the global oligonucleotide synthesis
market is segmented into three applications: research, diagnostic, and
therapeutic. The research application accounted for the largest share of
this market in 2018. The major share of research application is mainly
attributed to the rising adoption of oligonucleotides in drug discovery
& development with the recent development in the gene synthesis and
next-generation sequencing areas. A large number of oligos are commonly
used into various technologies such as PCR, qPCR/RTqPCR, gene synthesis,
sequencing, and SNP analysis. However, the diagnostics sector is
projected to register the fastest growth during the analysis period
owing to the advances in terms of detection methods, particularly with
respect to qPCR and sequencing techniques.

Geographically, the global oligonucleotide synthesis market is segmented
into five major regions, namely North America, Europe, Asia-Pacific,
Latin America, and Middle East & Africa. North America accounted for the
major share of the global oligonucleotide synthesis market in 2018,
followed by Europe and the Asia-Pacific region. The dominating position
of North America in the global oligonucleotide synthesis market is
mainly attributed to substantial growth in R&D investment; better
accessibility & higher adoption of technically advanced products; and
the presence of significantly improved infrastructure in the
biotechnology sector.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Insights

4.1. Introduction

4.2. Market Dynamics

4.2.1. Drivers

4.2.1.1. Growing Adoption of Synthesized Oligonucleotides in Diagnostics
and Clinical Applications

4.2.1.2. Rising R&D Expenditure and Government Investment in
Pharmaceutical and Biotechnology Companies

4.2.1.3. Plummeting Cost of Sequencing

4.2.1.4. Increasing Public-Private Spending on Genomics

4.2.1.5. Rising Venture Capital Investments/Funding

4.2.2. Restraints

4.2.2.1. Lack of Regulations for Therapeutic Oligos

4.2.2.2. Price Erosion of Synthesized Oligonucleotides

4.2.3. Opportunities

4.2.3.1. Emerging Asian Markets

4.2.3.2. Therapeutic Oligos

4.2.4. Challenges

4.2.4.1. Large-Scale Synthesis of Oligonucleotides

4.2.4.2. Delivery of Oligonucleotide Drugs to Specific Targets

5. Oligonucleotide Synthesis Market, by Product

5.1. Introduction

5.2. Synthesized Oligonucleotides

5.2.1. By Product

5.2.1.1. Primers

5.2.1.2. Probes

5.2.1.3. Large-Scale Synthesis Oligonucleotides

5.2.1.4. Intermediate-Scale Synthesis Oligonucleotides

5.2.1.5. Linkers & Adaptors

5.2.2. By Type

5.2.2.1. Custom Oligonucleotides

5.2.2.2. Pre-Designed Oligonucleotides

5.3. Reagents/Consumables

5.4. Equipment

6. Oligonucleotide Synthesis Market, by Application

6.1. Introduction

6.2. Research

6.2.1. PCR

6.2.2. qPCR/RTqPCR

6.2.3. Sequencing

6.2.4. Gene Synthesis

6.2.5. Other Research Applications

6.3. Diagnostics

6.4. Therapeutics

6.4.1. RNAi

6.4.2. Nucleic Acid Aptamers

6.4.3. DNA/Antisense Oligonucleotides

6.4.4. Immunotherapy Applications

7. Oligonucleotide Synthesis Market, by End User

7.1. Introduction

7.2. Academic Research Institutes

7.3. Pharmaceutical and Biotechnology Companies

7.4. Diagnostic Laboratories

7.5. Others

8. Oligonucleotide Synthesis Market, by Geography

8.1. North America

8.2. Europe

8.3. Asia-Pacific

8.4. Rest of the World

9. Competitive Landscape

9.1. Competitive Benchmarking

9.2. Market Share Analysis

10. Company Profiles (Includes Business Overview, Financial
Overview, Product Portfolio, and Strategic Developments)

10.1. Danaher Corporation

10.2. Merck KGaA (Sigma-Aldrich Co. LLC)

10.3. Eurofins Genomics LLC (Part of Eurofins Scientific SE)

10.4. Thermo Fisher Scientific, Inc.

10.5. Agilent Technologies Inc.

10.6. GE Healthcare

10.7. GeneDesign Inc. (Part of Ajinomoto Co. Inc.)

10.8. Kaneka Eurogentec S.A. (Part of Kaneka Corporation)

10.9. LGC Biosearch Technologies

10.10. Bio-synthesis Inc.

10.11. TriLink Biotechnologies LLC (Part of Maravai Lifesciences)

10.12. ATDBio Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/itq7nf

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology,
Genomics,
Drug
Discovery, Molecular
Diagnostics